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Abstract
Background: Mucus stasis in chronic obstructive pulmonary disease (COPD) is a significant contributor to morbidity and
mortality. Potentiators of cystic fibrosis transmembrane conductance regulator (CFTR) activity pharmacologically enhance
CFTR function; ivacaftor is one such agent approved to treat CF patients with the G551D-CFTR gating mutation. CFTR
potentiators may also be useful for other diseases of mucus stasis, including COPD.
Methods and Findings: In primary human bronchial epithelial cells, exposure to cigarette smoke extract diminished CFTR-
mediated anion transport (65.860.2% of control, P,0.005) and mucociliary transport (0.1760.05 mm/sec vs. 2.460.47 mm/
sec control, P,0.05) by reducing airway surface liquid depth (7.360.6 mm vs. 13.060.6 mm control, P,0.005) and
augmenting mucus expression (by 64%, P,0.05) without altering transepithelial resistance. Smokers with or without COPD
had reduced CFTR activity measured by nasal potential difference compared to age-matched non-smokers (26.361.4 and
28.062.0 mV, respectively vs. 215.262.7 mV control, each P,0.005, n=12–14/group); this CFTR decrement was
associated with symptoms of chronic bronchitis as measured by the Breathlessness Cough and Sputum Score (r=0.30,
P,0.05) despite controlling for smoking (r=0.31, P,0.05). Ivacaftor activated CFTR-dependent chloride transport in non-CF
epithelia and ameliorated the functional CFTR defect induced by smoke to 185636% of non-CF control (P,0.05), thereby
increasing airway surface liquid (from 7.360.6 mmt o1 0 . 1 60.4 mm, P,0.005) and mucociliary transport (from
0.2760.11 mm/s to 2.760.28 mm/s, P,0.005).
Conclusions: Cigarette smoking reduces CFTR activity and is causally related to reduced mucus transport in smokers due to
inhibition of CFTR dependent fluid transport. These effects are reversible by the CFTR potentiator ivacaftor, representing a
potential therapeutic strategy to augment mucociliary clearance in patients with smoking related lung disease.
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Introduction
Cystic fibrosis transmembrane conductance regulator (CFTR) is
an epithelial anion channel expressed predominantly in exocrine
tissues. Mutations in the gene encoding CFTR are the proximate
cause of CF [1]. In the lung, loss of CFTR function results in
airway surface liquid (ASL) depletion, reduced mucociliary
clearance (MCC), chronic bacterial infection, and excess inflam-
mation [2]. Over time, pulmonary obstruction due to inspisated
respiratory secretions and bronchiectasis ensues, resulting in
respiratory failure.
Individuals with smoking-induced lung disease, and in partic-
ular those with chronic obstructive pulmonary disease (COPD)
associated with chronic bronchitis [3,4], exhibit pathologic
features similar to CF, including mucus stasis and accumulation
[4,5,6]. While some COPD patients develop bronchiectasis [7],
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philic airway inflammation, pathophysiologic processes reminis-
cent of CF lung disease [8,9]. Mucus accumulation in COPD is
independently associated with lung function decline, exacerbation
frequency, and early mortality [10,11,12]. At present, no therapies
definitively address mucus accumulation in the COPD lung.
Emerging data suggest exposure to cigarette smoke causes
CFTR dysfunction in the upper airways. Cigarette smoke
inhibits chloride transport in cultured bronchial epithelial cells
[13,14], a finding supported in vivo by reduced CFTR-
dependent nasal potential difference (NPD) in the upper airways
of healthy smokers without CFTR mutations [13]. The
development of efficacious modulators of CFTR anion transport
has raised the possibility that pharmacologic enhancement of
CFTR activity may have important clinical significance, even
among individuals without congenital CFTR mutations. The
novel CFTR potentiator ivacaftor (Kalydeco
TM, VX-770) was
recently approved for use in CF patients with the G551D-
CFTR gating mutation based on marked improvements in
multiple clinical endpoints in phase 2 and 3 trials [15,16].
Ivacaftor robustly enhances anion secretion by potentiating
cAMP mediated CFTR channel gating [17] leading to airway
fluid secretion, and points to novel treatment strategies for
common diseases of mucus stasis, including COPD caused by
cigarette smoking [18]. In these studies we tested the hypothesis
that cigarette exposure has deleterious effects on mucociliary
transport by causing an imbalance of CFTR mediated fluid
secretion and enhanced mucus expression. Complementary
studies in smokers with and without COPD suggested CFTR
dysfunction is present, and thus may represent a viable
therapeutic target. Our in vitro studies establish that the
functional CFTR deficiency caused by smoke exposure can be
ameliorated by addition of ivacaftor, thereby augmenting airway
surface liquid depth and mucociliary transport. These findings
suggest that CFTR potentiators may offer a new treatment
paradigm for COPD associated with chronic bronchitis.
Methods
Procurement and Growth of Primary Airway Epithelial
Cells
Use of human cells and tissues was approved by the UAB
Institutional Review Board. Primary human bronchial epithelial
cells were derived from lung explants after written informed
consent was obtained from CF and non-CF subjects with
confirmed CFTR genetics by methods described previously
[17,19]. Briefly, tissues were debrided immediately after surgical
resection, washed twice in Minimum Essential Media with
0.5 mg/ml DTT (Sigma-Aldrich, St. Louis, MO) and 25 U/ml
DNAse I (Roche, Basel, Switzerland), and then placed in
dissociation media containing MEM, 2.5 U/ml DNAse I,
100 mg/ml ceftazidime, 80 mg/ml tobramycin, 1.25 mg/ml am-
photericin B, and 4.4 U/ml pronase (Sigma-Aldrich) for 24–36 h
at 4uC. Loosened airway epithelial cells were then expanded in
growth media containing BEGM (LONZA, Basel, Switzerland)
supplemented with an additional 10 nM all trans-retinoic acid
(Sigma-Aldrich) that was exchanged every 24 h. Following
expansion, first or second passage cells were seeded on permeable
supports for studies.
Once 80–90% confluent, cells were seeded on Snapwell
1.13 cm
2 permeable supports (1610
6 cells/filter; Bayer, Pitts-
burgh, PN) or Costar 0.4 mm permeable supports (5610
5 cells/
filter; Bethesda, MD) after coating with NIH 3T3 fibroblast
conditioned media, and grown in differentiating media containing
DMEM/F12 (Invitrogen, Carlsbad, California), 2% Ultroser-G
(Pall, New York, NY), 2% Fetal Clone II (Hyclone, Logan, UT),
2.5 mg/ml Insulin (Sigma-Aldrich), 0.25% bovine brain extract
(LONZA), 20 nM hydrocortisone (Sigma-Aldrich), 500 nM Trio-
dothyronine (Sigma-Aldrich), 2.5 mg/ml transferrin (Invitrogen),
250 nM ethanolamine (Sigma-Aldrich), 1.5 mM epinephrine
(Sigma-Aldrich), 250 nM phosphoetheanolamine (Sigma-Aldrich),
and 10 nM all trans-retinoic acid until terminally differentiated, as
previously described [17,19].
Voltage Clamp Studies in Ussing Chambers
Short-circuit current (Isc) was measured under voltage clamp
conditions using MC8 voltage clamps and P2300 Ussing chambers
(Physiologic Instruments, San Diego, CA) as previously described
[19]. Monolayers were initially bathed on both sides with identical
Ringer’s solutions containing (in mM) 115 NaCl, 25 NaHCO3,
2.4 KH2PO4, 1.24 K2HPO4, 1.2 CaCl2, 1.2 MgCl2,1 0D -
glucose (pH 7.4). Bath solutions were vigorously stirred and gassed
with 95%O2:5% CO2. Short-circuit current measurements were
obtained using an epithelial voltage clamp (Physiologic Instru-
ments). A one-second three-mV pulse was imposed every 10
seconds to monitor resistance calculated using Ohm’s law. Where
indicated, the mucosal bathing solution was changed to a low Cl
2
solution containing 1.2 NaCl and 115 Na
+ gluconate, and all
other components as above. Amiloride (100 mM) was added to
block residual Na
+ current, followed by the agonists forskolin,
ivacaftor, and ATP as indicated (minimum five-min observation at
each concentration). CFTRInh-172 (10 mM) was added to the
mucosal bathing solution at the end of experiments to block
CFTR-dependent Isc. All chambers were maintained at 37uC, and
agonist stimulation was initiated within 15 min of placement into
the chambers.
CFTR Western Blotting
Cells were washed with ice-cold 16PBS twice, then lysed with
ice-cold RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris?HCl) containing
protease inhibitors (Thermoscientific, Waltham, MA). Lysates
were centrifuged at 14,000 g for 15 min at 4uC. Equal amounts of
protein were electrophoresed on SDS-PAGE gels (Invitrogen,
Carlsbad, CA) then transferred to nitrocellulose membranes
(BioRad Laboratories, Hercules, CA). Blots were blocked in 16
PBS containing 5% (w/v) milk powder and 0.1% Tween-20, then
incubated with 1:500 diluted anti-CFTR antibody (Millipore
Corporation, Billerica, MA) overnight at 4uC, washed, followed by
secondary antibody (Dako, Carpinteria, CA) conjugated with
horseradish peroxidase 1:3000 for 1 h at room temperature.
Chemiluminescence was induced with high-sensitivity Immobilon
Western substrate (Millipore, Billerica, MA). The membranes
were exposed using CemiDoc XRS HQ (Bio-Rad, Hercules, CA,
USA) for different periods (up to 2 min) and calibrated in the
linear range for a standard set of diluted samples [20].
Cell-surface CFTR Biotinylation Studies
All cell surface glycoproteins were biotinylated similar to that
previously described [19]. Biotinylated protein was immunopre-
cipitated using NeutrAvidin beads, separated by SDS-PAGE gel
and detected by Western blot. CFTR was detected with anti-
CFTR NBD1 10B6.2 polyclonal antibody followed by enhanced
chemiluminescence (ECL; Pierce Biotechnology, Inc., Rockford,
IL, USA).
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A TaqMan One-Step RT-PCR protocol (Applied Biosystems,
Foster City, CA) was used to quantify CFTR mRNA transcripts
using Assays on Demand Gene Expression Products, coupled with
the ABI Prism 7500 sequence detection system (Applied Biosys-
tems) as previously described for both nasal curettage and primary
airway cell specimens [21,22]. Briefly, total RNA was isolated
using the Qiagen RNeasy mini kit according to manufacturer’s
instructions. To prevent possible DNA contamination, samples
were pretreated with RNase-free DNase (Qiagen, Valencia, CA).
Sequence specific primers and probes for human CFTR and 18S
rRNA were purchased from Assays on Demand (Applied
Biosystems); Assay ID for CFTR: Hs00357011_m1. The probe
extends across the exon 21/22 boundary of the human CFTR
sequence. TaqMan One Step PCR Master Mix Reagents Kit
(Applied Biosystems) was used for reverse transcription and PCR.
The reaction volume was 25 ml and contained 12.5 mlo f2 6
Master Mix without uracil-N-glycosylase, 0.625 mlo f4 0 6Multi-
Scribe and RNase Inhibitor Mix, 1.25 mlo f2 0 6target primer and
probe, 5.625 ml of nuclease-free water (Ambion, Austin, TX), and
5 ml of RNA sample. Reaction plates were covered with an optical
cap and centrifuged briefly to remove bubbles. Thermocycler
conditions were as follows: Stage 1: 48uC for 30 min; Stage 2:
95uC for 10 min; Stage 3: 95uC for 15 sec, repeat 40 cycles, 60uC
for 1 min. All experiments were run in triplicate for verification.
The relative quantification of transcript levels (CFTR compared
with endogenous 18S rRNA) was performed using the standard
curve method.
Mucin Histochemistry
Cultured airway cells were fixed with cold neutral buffered
formalin for 60 min, then permeable supports stabilized in
HistoGel (Richar-Allan Scientific, Kalamazoo, MI) before paraffin
embedding. Thin sections from each filter were stained with H&E
and PAS, and the number of PAS positive cells quantified by
inspection by a single-blinded investigator. Fifty cells minimum
were assessed per exposed filter. For MUC5ac antibody staining,
slides were processed for antigen retrieval in pH 9.0 buffer
(10 mM Tris, 1 mM EDTA), boiled for ten minutes at 15 PSI,
then washed with 3% aqueous hydrogen peroxide for 5 min to
quench endogenous peroxidase and afterwards rinsed with Tris
buffer. Three percent goat serum was added for 20 min to block
non-specific binding, then slides were incubated with monoclonal
anti-MUC5ac antibody (1–13 M1,Neomarker, CA) diluted
1:200 in PBE (1% BSA and 1 mM EDTA,in PBS at pH 7.6)
buffer overnight in a humidity chamber at 46C. Slides were then
incubated at 256C for 20 min with anti-mouse HRP secondary
antibody (1:200, Jackson Immuno Research) in PBE buffer. The
slides were rinsed with Tris buffer and diaminobenzidine
tetrachloride supersensitive substrate kit (Bio-Genex) was used to
visualize the HRP reaction. Slides were counterstained with weak
Mayer’s hematoxylin solution for 2 min. Negative control slides
were prepared without addition of primary antibody.
Cellular cAMP Measurements
Cellular cAMP was measured using an ELISA-based detection
kit (Cayman Chemicals, Ann Arbor, MI) as previously described
[22,23]. Briefly, fully differentiated airway cells were stimulated
with forskolin or vehicle control for 10 min, and cellular cAMP
was extracted with ice-cold ethanol. The supernatants were
vacuum dried, resuspended in phosphate buffer, and cAMP levels
quantified per manufacturer’s directions.
Mucus Transport Studies
HBE cells were washed with sterile PBS twice 1–2 days prior to
addition of PEG beads. Fifty (50) ml of Diamine polyethylene
glycol (PEG) coated fluorescent beads (1 mm, Molecular Probes,
Eugene, OR, 1:500 dilution in PBS) were added to the apical
surface by using a microsprayer aerosolizer (Penn-Century
IncModel IA-1B, Wyndmoor, PA). Following 24 h incubation,
baseline images were obtained and then test compounds added to
the basolateral compartment. Mucociliary transport (MCT)
images were captured by time-lapse fluorescence imaging at four
regions of interest per well located 1 mm from the periphery of the
well and at each quadrant using an inverted epifluorescence
microscope (Nikon Diaphot, Melvin, NY; 488 nm excitation/
519 nm emission). Linear transport rates were computed using
Metamorph 7.0 by analyzing 10–15 particles per region [24].
Ciliary Beat Frequency (CBF) Analysis
HBE cells were allowed to equilibrate to room temperature for
15 min, then monitored by Hoffman contracts microscopy at 4–5
ROI for each well using high-speed digital video imaging at 100
frames/s, as previously described [25]. CBF was detected using
Sisson-Avon Video Analysis (SAVA, Ammons Engineering, Mt.
Morris, MI). Change in CBF was calculated as the change from
baseline CBF detected in the same well 24 hours prior to addition
of experimental conditions, normalized for the change in CBF
observed with vehicle.
Airway Surface Liquid (ASL) Depth Measurement by
Confocal Microscopy
The apical surfaces of HBE cells were washed three times and
then test compounds added to the basolateral compartment 24 h
prior to labeling. Cells were stained with CMFDA (100 mM) in the
cell culture medium for 1 hr. Texas red dye (25 ml at 10 mg/ml in
Fc70) was added apically and cells allowed to equilibrate 2 h at
37uC. Transwell membranes were placed in sterile glass bottom
dish coated with MEM, and imaged with a Carl Zeiss (Peabody,
MA) confocal microscope using 206 (numerical aperture 0.88,
working distance 0.55 mm) air objective lens. Cells were visualized
with DIC optics to evaluate cell morphology before initiating
fluorescence microscopy. Subsequently, Z-scan confocal fluores-
cent microscopy images were acquired from the top of the ASL
through the top of the cell surface. XZ scans were analyzed using
Zen2008 software at four ROI per well each located 1 mm from
the filter periphery and at each quadrant; 5 estimates of ASL
depth were taken equally dispersed across each ROI [24,26].
Because baseline ASL depth varies among donors, each experi-
ment was internally controlled using cells derived from a single
donor.
Nasal Potential Difference Measurements in Human
Subjects
NPD protocols were approved by the University of Alabama at
Birmingham’s IRB, and all subjects provided written informed
consent. Inclusion criteria required age 40–80 and no respiratory
illness in the last month that required antibiotics or steroids. A
minimum of 10 pack-years tobacco use was required for all COPD
patients, and current smokers were defined as smoking at least 10
cigarettes daily. Former smokers must have been abstinent for $1
year confirmed by measurement of urine cotinine. COPD patients
must also have had a post-bronchodilator FEV1/FVC ratio ,70%
and an FEV1 between 40 and 70% predicted. Exclusion criteria
include asthma or other lung disease or a change in medications
one month prior to enrollment. The presence and severity of
An Approach to Acquired CFTR Dysfunction
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Score (BCSS) as described by Leidy et al [27].
NPD studies were performed based on the description by
Solomon et al.[28] and the Standard Operating Procedure of the
CF-Therapeutics Development Network (Non-Perfusion method;
SOP 528.00) using Electronic Data Capture (AD Instruments,
Colorado Springs, CO), KCl calomel electrodes (Fischer Scientific,
Pittsburgh, PA) and 3% agar nasal catheter and reference bridges.
CFTR Genetics
CFTR genetic testing (50 mutation analysis) was performed on
all airway tissue samples and NPD participants at a commercially
accredited facility (Baylor Medical Genetics, Houston, TX), and
included the 23 mutations recommended by the American College
of Medical Genetics (ACMG) and reflex testing of the 5T allele
upon detection of the R117H mutation.
Reagents
Forskolin (Calbiochem; San Diego, CA), ATP (Sigma-Aldrich),
vasoactive intestinal peptide (Sigma-Aldrich), CFTRInh-172 (Cal-
biochem), and ivacaftor (Exclusive Chemistry, Obninsk, Russia)
were used for experiments. Organically soluble cigarette smoke
extract (CSE) was prepared by bubbling smoke from 1 2R4
research cig/ml DMSO (University of Kentucky, Lexington, KY)
at 2 sec/10 ml puff/over 3 min to make 100% extract
(OD320=0.2 at 100-fold dilution), then applied to cells diluted
in media at the percentages shown, as previously described [29]. A
volume of 25 mL CSE in media was applied to 0.33 cm
2 transwell
filters, and the exact same volume of media with DMSO vehicle
was applied to controls. CSE at this concentration is thought to
resemble exposures of cigarette smoke experienced in moderately
heavy smokers [30,31,32], including the organically soluble form.
Statistics
For Isc, cAMP measurements, Western blot densitometry,
mucus transport rates, cilia beat frequency, and airway surface
liquid depth, and potential difference measurements, descriptive
statistics (mean, SD, and SEM) were compared using Student’s t-
test or ANOVA, as appropriate. Post-hoc tests for multiple
comparisons following ANOVA were calculated using Fisher’s
least significant difference. All statistical tests were two-sided and
were performed at a 5% significance level (i.e., a ´ =0.05) using
GraphPad Prism (La Jolla, CA). Error bars designate SEM unless
indicated otherwise. Correlation analysis was performed using
SPSS (IBM, Armonk, NY).
Results
To establish that exposure to cigarette smoke inhibits CFTR-
dependent ion transport in our model, we exposed the apical
surfaces of fully differentiated primary airway epithelial cells (HBE)
derived from non-CF (wild-type) donors to increasing concentra-
tions of organically soluble CSE, mimicking exposure levels in
cigarette smokers [30,31,32]. As shown in Fig. 1A–C, CSE
reduced the cAMP-dependent current in a dose-dependent fashion
and at concentrations that did not alter transepithelial resistance
(133.1611.1 V?cm
2 (control) vs. 168.7615.6 (CSE 2%), P=0.84).
Changes in CFTR activity were accompanied by reduced delivery
of CFTR to the cell surface, demonstrated by a reduction in the
steady-state levels of fully-glycosylated CFTR (mature C band)
compared to untreated controls (Fig. 1E,E) and cell-surface CFTR
determined by a biotinylation assay (Fig. 1F,G). Similarly, CFTR
mRNA transcript levels were reduced in CSE-treated monolayers
compared to untreated controls assessed by real-time RT-PCR
(Fig. 1H). The effects of CSE on ion transport were confirmed in
Calu-3 cells, a model of airway serous glandular epithelium that
exhibits high levels of endogenous wild-type (WT)-CFTR expres-
sion (Fig. S1A,B). Cyclic AMP levels were modestly elevated in
HBE cells exposed to CSE for 24 h, establishing that reduced
cAMP did not underlie the deleterious effects on CFTR activity.
Cyclic AMP levels induced by CSE were equivalent to concen-
trations observed following addition of 130 nM forskolin based on
a standard curve (Fig. 1I and Fig. S2). These results suggest that
CSE reduced CFTR-dependent anion transport in part due to
reduced delivery of CFTR to the cell surface resulting in deficient
epithelial anion transport, thus extending prior reports with CSE
[13,14] and gas phase cigarette smoke [33].
Given the deleterious effects of CSE on CFTR-dependent anion
conductance, we next examined the impact of CSE exposure on
mucus expression and mucociliary transport. CSE exposure
generated a pronounced increase in mucus expression measured
by histologic staining of PAS positive material (Fig. 2A,B).
MUC5ac was highly expressed in CSE-exposed HBE cells, similar
to the phenotypic expression in the bronchi of human smokers
(Fig. S3) [34]. The changes in CFTR activity and mucus
expression induced by CSE were associated with prominent
reductions in mucociliary transport rates measured by fluorescence
microscopy (Fig. 2C).
Given the effects of CSE on CFTR-dependent ion transport
and mucus transport in respiratory epithelial cells, we next
assessed whether this defect is also detectable in vivo among
individuals with smoking related COPD. While reduced CFTR
activity has been previously reported in healthy smokers without
CFTR mutations, individuals with COPD have not been studied
[13]. Because ion transport defects in primary respiratory
epithelial cells are highly predictive of ion transport in vivo
Figure 1. Cigarette smoke reduces CFTR-dependent activity and expression. (A) Representative tracings from primary human bronchial
epithelial cells were grown at air-liquid interface until fully differentiated, followed by exposure to cigarette smoke extract (CSE 2%) on the apical
surfaces for 24 h. Cells were then mounted in modified Ussing chambers and sequentially exposed to forskolin (20 mM) and CFTRInh-172 (10 mM) in
the setting of amiloride (100 mM) and Cl
–free gluconate on the apical compartment. (B–C) Summary data of experiments shown outlined in (A).
Change in short-circuit current (Isc) following addition of forskolin is shown as a percentage of wild-type non-CF current and absolute Isc (B). Change
following 2% CSE is also shown for CFTRInh-172 (10 mM, C). *P,0.05, **P,0.005, n=4 per concentration. (D) Western blot of cell lysates of primary
HBE cells shown in (A) harvested immediately after treatment in the Ussing chamber. CFTR bands B and C are shown by the black and white arrows,
respectively. All lanes were normalized for protein concentration and no difference was observed in protein levels at baseline: vehicle control treated
wells (1.7960.37 mg/ml) vs. CSE treated wells (1.9260.40 mg/ml; P=0.81); a-tubulin is also shown as a loading control. This blot is representative of
3 similar experiments. (E) Densitometry of CFTR band C shown in (D). **P,0.01. (F) Surface CFTR expression was quantified by a cell surface
biotinylation assay following CSE (2%) or vehicle control treatment for 24 hrs. Blot is representative of 3 similar experiments. (G) Densitometry of
surface CFTR band shown in (F). *P,0.05. (H) Primary HBE cells were exposed to CSE (2%) 24 h, then RNA isolated, and quantitative RT-PCR
performed in comparison to 18S RNA. *P,0.05, n=9/condition. (I) cAMP concentration in HBE cells exposed to CSE (2%) or vehicle control for 24 h
prior to assay. Equivalent forskolin concentration was calculated based on a standard curve in the same cells (See Fig. S2). *P,0.05.
doi:10.1371/journal.pone.0039809.g001
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COPD would be characterized by reduced CFTR expression and
activity measured by nasal potential difference (NPD). We enrolled
individuals with COPD who currently smoke and compared
CFTR-dependent chloride transport to results observed in age-
matched healthy controls, smokers without airflow obstruction,
and COPD subjects who had quit smoking for at least 1 year
(Table 1). One healthy non-smoker control was identified as a CF
carrier, and was excluded from the analysis. Smokers with COPD
exhibited a severe reduction in CFTR-dependent ion transport
(Fig. 3A,B) that was slightly lower than healthy smokers; the
chloride conductance of former smokers with COPD was not
affected (Fig. 3A,B), indicating that CFTR function can recover
following prolonged smoking cessation. Baseline voltage was
7.760.8 in COPD smokers compared to 13.662.4 in healthy
controls (P,0.05) and amiloride sensitive PD was also reduced in
COPD smokers, suggesting that unlike CF, smoking is not
associated with baseline hyperpolarization of the nasal membrane.
The defect in chloride conductance from smoking was not
attributable to changes in mucosal integrity and appeared specific
to CFTR, as no significant difference in PD was observed
following adenosine triphosphate (ATP) perfusion, which stimu-
lates activity of Cl
2 channels other than CFTR (Fig. 3C). We also
observed a specific reduction in CFTR mRNA expression in nasal
curettage samples obtained from individuals with COPD (Fig. 3D).
Reduced CFTR activity measured by NPD was also associated
with the severity of bronchitic symptoms (r=0.30, P,0.05), as
assessed by BCSS [27], even when controlled for cigarette smoking
(r=0.31, P,0.05), indicating an association with a phenotype
reminiscent of CF (i.e. chronic bronchitis).
Recently the potentiator ivacaftor was reported to significantly
augment cAMP mediated ion transport activity of CFTR
encoding the gating mutation, G551D-CFTR, in vitro [17] and
in CF subjects harboring the G551D CFTR defect [16]. Ivacaftor
improved measures of CFTR activity (including both chloride
conductance monitored by NPD and sweat chloride [16]) and also
produced a marked and sustained improvement in pulmonary
function in CF patients with G551D-CFTR [15,16], establishing
that mutant CFTR is a valid therapeutic target in CF. To assess
whether ivacaftor also promotes the anion channel activity of WT-
CFTR, which could thereby serve as a therapeutic target in
acquired disorders of CFTR function, we examined the activity of
Figure 2. Mucociliary transport is inhibited by CSE. (A) Representative photomicrograph of fully differentiated HBE cells exposed to CSE (2%,
apical) or vehicle control for 24 h then fixed, sectioned, and stained with PAS. PAS staining of intracellular and extracellular mucus shows as dark red.
Scale bar depicts 25 mm. (B) Summary data of proportion of PAS positive cells from slides shown in (A). *P=0.05, n=7–10/condition. (C) HBE cells
were exposed to CSE (2%) or vehicle control, and transport rates of 1 mm fluorescent particles monitored. Baseline measures were made 24 h
preceding time 0 h, followed by application of CSE or vehicle, then monitored at the times indicated. All results are normalized to transport rate at
time 0 h for each individual well. *P,0.05, **P,0.001, n=10 particles/well.
doi:10.1371/journal.pone.0039809.g002
An Approach to Acquired CFTR Dysfunction
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39809ivacaftor in WT-CFTR expressing cells. Ivacaftor induced robust
increases in anion transport in CFBE41o- cells complemented with
stable WT-CFTR expression, whereas no activity was observed in
parental cells without detectable CFTR expression, establishing
specificity for CFTR (Fig. 4A). The increase in anion transport by
ivacaftor was related to a pronounced increase in the open
probability of WT-CFTR expressed in NIH 3T3 cells (Fig. S4) as
measured by single channel studies using an inside-out membrane
patch configuration. In primary non-CF HBE cells, ivacaftor also
augmented CFTR-dependent anion transport activity following
pre-stimulation with 100 nM forskolin, a dose chosen to induce
cAMP levels matching CSE-exposed cells, increasing CFTR-
dependent short-circuit current (Isc) stimulated by forskolin alone
(Fig. 4B,C). The activity of ivacaftor in WT-CFTR expressing cells
varied according to the degree of forskolin pre-stimulation in HBE
cells (Fig. S5), and was maximal at concentrations approximating
10–100 nM forskolin. The increase in CFTR function by ivacaftor
was associated with increased ASL depth of non-CF HBE
Table 1. Demographics of Study Subjects.
Non-smokers without
COPD Non-smokers with COPD Smokers with COPD Smokers without COPD
(n=8) (n=12) (n=12) (n=12)
Age
Mean 57 66.7 55.6 51
Range 45–74 66–77 49–66 47–57
Gender, Female
n (%) 5 (62.5) 6 (50) 5 (42) 5 (42)
Smoking history – pack years
Mean 0 48.2 55.1 33.2
Range 0 35–80 35–78 10–78
FEV1/FVC, mean 0.80 0.50 0.53 0.79
FEV1% predicted
Mean 99 56.9 54.1 92.2
Range 74–123 43–73 32–82 76–114
doi:10.1371/journal.pone.0039809.t001
Figure 3. Reduced CFTR activity in smokers with COPD measured by potential difference. (A) Representative nasal potential difference
(NPD) tracings from a normal subject, a smoker with COPD, a COPD subject who no longer smokes and a healthy smoker are shown. Nasal membrane
was sequentially perfused with Ringer’s solution, Ringer’s plus amiloride (100 mM), Cl
–free gluconate with amiloride, Cl
–free gluconate with amiloride
plus isoproterenol (100 mM), and Cl
–free gluconate with amiloride plus isoproterenol and ATP (10 mM). A CF subject is shown for comparison. (B–C)
Summary data derived from subjects shown in (A) demonstrating CFTR-dependent Cl
2 conductance (DCl
–
free + Iso, B) and DPD following ATP
perfusion (C). *P,0.05, **P,0.005. (D) CFTR mRNA expression determined by real-time RT-PCR and normalized to 18S endogenous control. Levels
are expressed relative to mean mRNA level in normal subjects.
tP=0.07, n=16, 13.
doi:10.1371/journal.pone.0039809.g003
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39809Figure 4. The CFTR potentiator ivacaftor augments wild-type CFTR anion transport resulting in enhanced mucus transport. (A)
CFBE41o- cells were grown at air-liquid interface, then mounted in Ussing chambers and stimulated with ivacaftor (10 mM) or vehicle control
following amiloride (100 mM) and forskolin (100 nM) in the setting of a Cl
2 secretory gradient. CFBE41o- cells complemented by stable expression of
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ment, reflecting augmented CFTR-dependent fluid transport
(Fig. 4D,E). While ivacaftor induced a modest but significant
increase in ASL depth, the effects on MCT were dramatic at 24 h
(Fig. 4F). Ivacaftor also potentiated CFTR-dependent current in
normal explanted human trachea examined under voltage clamp
conditions (Fig. 4G,H); the effects of ivacaftor were similar
(P=NS) whether the individual was an active smoker
(6.865.6 mA/cm
2) or non-smoker (9.963.4 mA/cm
2), suggesting
the therapeutic potential of ivacaftor in individuals with a history
of smoking.
Given the robust effects of ivacaftor in non-CF epithelia,
including potentiation of CFTR-mediated ion transport, ASL
depth, and MCT, we next examined whether CSE mediated
CFTR inhibition could be overcome by application of ivacaftor,
and the resultant effects on ASL and MCT. Ivacaftor potentiated
CFTR-dependent Isc, regardless of prior administration of CSE
(Fig. 5A,B). Ivacaftor partially restored depletion of ASL depth in
CSE treated monolayers (Fig. 5C,D) and also caused a significant
increase in MCT rate (Fig. 5E), though ciliary beating was only
minimally affected (Fig. S6).
Discussion
We demonstrate that acquired CFTR dysfunction induced by
cigarette smoke contributes to mucus stasis, an important predictor
of morbidity and mortality in COPD [10,12], and that this
abnormality is markedly improved by the CFTR potentiator
ivacaftor in vitro. Moreover, the results provide a strong basis to
consider CFTR potentiator treatment as a pharmacologic strategy
to directly address acquired CFTR dysfunction in COPD using a
treatment already available for CF.
The deleterious effects of cigarette smoke exposure on anion
transport in respiratory epithelia were first observed in dog trachea
by Welsh prior to CFTR gene discovery [36]. Kreindler et al.
implicated CFTR when demonstrating that CSE altered chloride
and potassium conductance in primary non-CF HBE cell cultures
[14], findings later confirmed with gas phase cigarette smoke by
Savitski et al. [33]. These data also support Cantin et al. who
demonstrated that CFTR mRNA, protein expression and ion
transport were reduced in Calu-3 cells following CSE exposure in
vitro and that chloride transport was impaired in NPD testing of
healthy smokers without CFTR mutations [13]. Our observations
regarding the effects of cigarette smoke on CFTR-mediated ion
transport now include smokers with COPD. The downstream
effects of cigarette exposure on mucus expression and transport
shown here are natural consequences of an altered ion transport
milieu and form the basis for evaluating compounds that target
CFTR activation. Although former smokers with COPD largely
recover CFTR activity as assessed by NPD, we do not yet know
whether CFTR function normalizes in the lung, where additional
insults may also contribute to CFTR deficiency. Regardless, our
results indicate that individuals with sustained CFTR dysfunction
are more predisposed to symptoms attributable to delayed
mucociliary transport, including the severity of daily chronic
cough independent of current cigarette smoking.
Our findings provide a clear indication that cigarette smoke
exposure and the associated decrease in CFTR function is causally
related to decreased mucociliary transport observed in smokers
with COPD. When the effect of cigarette smoke on CFTR-
dependent fluid secretion is accompanied by augmented mucus
expression, MCT is markedly decreased (Fig. 6). Our findings
demonstrate the importance of the fluid secretion/mucus expres-
sion balance required to regulate mucus clearance, a hypothesis
previously postulated by Kreindler [14]. Measurements of
transepithelial resistance, direct visualization following fixation,
immunohistochemistry, CFTR-dependent ion transport stimula-
tion, ASL depth measurements and fluorescent particle mobility
confirm the assertion that the effects of CSE are mediated through
CFTR-dependent fluid secretion, and not simply due to disruption
of the integrity of cell monolayers.
An improved understanding of the role of CFTR in the
maintenance of normal epithelial function has revealed that mild/
variable CFTR mutations also play a causative role in a number of
diseases not classically associated with CF. For example, mild/
variable CFTR mutations are present in ,30% of individuals with
recurrent idiopathic pancreatitis [37,38], and similar associations
have been established in congenital bilateral absence of the vas
deferens [39], allergic bronchopulmonary aspergillosis [40,41],
chronic sinusitis [42], and idiopathic bronchiectasis [43,44]. The
basis of these diseases illustrate that mild CFTR dysfunction can
contribute to substantial pathology, even among individuals not
previously recognized to have dysfunctional ion transport [45].
Although we observed only a partial inhibition of CFTR activity
following cigarette smoke exposure in vivo or in vitro, the functional
decrement is equivalent to that observed in individuals with mild/
variable CFTR mutations associated with clinical CF and
significantly greater than asymptomatic heterozygotes [46].
Combined with increased mucus expression expected following
cigarette smoking (and observed in our studies), we posit that these
abnormalities are sufficient to induce a severe abnormality in
MCT in the lung and contribute to mucus stasis in the small
airways, resulting in symptoms of chronic bronchitis. Delayed
MCT through this pathway may also be responsible for reduced
MCC detected in individuals with chronic bronchitis in compar-
ison to COPD patients without chronic mucus expectoration [47].
The robust response of MCT to the application of the CFTR
potentiator ivacaftor, an agent with a high degree of selectivity for
CFTR [17], further strengthens the argument that deficient
CFTR activity has an important role governing delayed MCC in
smoking-related lung diseases (Fig. 6).
Because animal models of smoking induced bronchitis that also
exhibit lung disease attributable to CFTR mutations are not
WT-CFTR (by a lentivirus promoter) are shown in comparison to CFBE41o- cells without WT CFTR complementation (parental cells). *P,0.05,
**P,0.005, n=5/condition. (B) Representative Isc tracings of primary HBE cells sequentially exposed to forskolin (100 nM), ivacaftor (10 mM) or
vehicle control, followed by CFTRInh-172 (10 mM) in the setting of amiloride (100 mM) and a chloride secretory gradient. (C) Summary data of tracings
shown in (B) indicating stimulated Isc following acute addition of ivacaftor. ** P,0.005, ***P,0.0005, n=5–6/condition. (D) Representative Z-scan
confocal images derived from HBE cells following exposure to vehicle control or ivacaftor (10 mM) to the basolateral compartment for 24 h prior to
assay. White scale bars designate 10 mm. (E) Summary data from experiments shown in (D). **P,0.005, n=10/condition. (F) Mucociliary transport
rates derived from HBE cells. ivacaftor (10 mM) or vehicle control was added to basolateral compartment of monolayers co-stimulated with the cAMP
agonist VIP (30 nM) immediately after the time =0 h measurement. **P,0.005 vs. vehicle control, n=10 particles/condition. (G) Representative Isc
tracing of bronchus derived from a normal human subject following dissection of the mucosal layer that was then mounted in an Ussing chamber
under voltage clamp conditions and bathed in symmetric Ringer’s solution. Serial addition of amiloride (100 mM), forskolin (100 nM), and ivacaftor
(10 mM) or vehicle control is shown, followed by addition of ATP (10 mM), and CFTRInh-172 (10 mM62) as control additions. (H) Summary data derived
from experiments shown in (G). The change in Isc following addition of ivacaftor or vehicle control is shown. *P,0.05, n=19, 24 samples/condition.
doi:10.1371/journal.pone.0039809.g004
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the present findings were largely focused on the use of primary
bronchial epithelial cell cultures, complemented by evaluation of
intact tissues and in vivo measures in human subjects. An important
strength of the HBE model is that it is highly representative of the
ion transport environment in the human airway [24] and
predictive of pharmacologic benefit with CFTR modulators in
CF [17]. This relationship is borne out by our studies, which also
demonstrate a close resemblance between in vitro and in vivo
measurements of ion transport. Though the HBE model faithfully
replicates in vivo findings in CF, we do not yet have evidence that
ivacaftor augments CFTR activity in vivo in individuals without
CF. Moreover, our experimental model relies on acute exposure to
cigarette smoke, and cannot account for the myriad of
pathophysiologic pathways and compensatory mechanisms that
are induced with chronic smoking and may impact MCT,
including the effects of squamous metaplasia, glandular hypertro-
phy, or subepithelial inflammation. Of note, the effect of ivacaftor
Figure 5. The CFTR Potentiator ivacaftor rescues block of CSE-induced CFTR-dependent epithelial function. (A) Primary HBE cells were
treated with 2% CSE or vehicle control for 24 h, then studied under voltage clamp conditions. Cells were stimulated with forskolin (100 nM), ivacaftor
(10 mM) or vehicle control, and then CFTRInh-172 (10 mM) to block CFTR. (B) Summary data of experiments shown in (A). Total stimulated Isc (forskolin
+ ivacaftor or vehicle control) is shown as the percentage of wild-type Isc with forskolin (100 nM) alone, n=6 per condition. (C) Representative Z-scan
confocal images derived from HBE cells following exposure to CSE (2%, apical), CSE + ivacaftor (10 mM basolateral), or vehicle control for 24 h prior to
assay. White scale bars designate 10 mm. (D) Summary data from experiments shown in (C). **P,0.005, n=15/condition. Dotted line indicates ASL
depth of a panel of CF HBE cells using the exact same method. (E) Mucociilary transport studies were performed in HBE cells using movement of
fluorescent beads 1 mm from the filter periphery. Beads were added 24 h prior to time 0 h measurements, then CSE (2%) was added to the apical
compartment in addition to ivacaftor (10 mM) or vehicle control to the basolateral compartment. *P,0.05.
doi:10.1371/journal.pone.0039809.g005
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on ASL depth or ciliary beating, suggesting that the MCT
apparatus is highly sensitive to fluid secretion. We do not yet know
whether the improvement in MCT may be in part due to changes
in mucus viscosity, adherence, or relative sensitivity of mucosal
transport to fluid secretion. It is also possible that ivacaftor may
lead to reduced mucin expression which could contribute to these
robust effects, though this was not reported in preclinical testing of
the compound.
Our studies show that reduced CFTR function caused by
smoking was not associated with increased sodium transport, as
commonly observed in CF. Rather, reduced CFTR mediated
anion secretion appears to be the major cause of reduced ASL
depth induced by smoking, though other ion transport pathways
not measured by our studies could also contribute. Notably, a
trend towards reduced sodium conductance was also reported by
Cantin and Kreindler (12, 13) supporting our findings and
highlighting that the changes in epithelial function caused by
smoking are more complex than those observed when CFTR is
genetically absent. Regardless of the relative contributions of other
ion transport pathways, the robust effects of ivacaftor on ASL
depth and MCT rates strongly indicate that increased chloride
transport is sufficient to augment epithelial function and provide a
compelling rationale to consider testing CFTR potentiators in
individuals with smoking-related COPD, regardless of the status of
sodium transport.
Other noxious stimuli particularly relevant to the COPD lower
airway have recently been postulated to reduce CFTR activity,
and may contribute to the in vivo deficit. Heavy metals, such as
cadmium, have been proposed to be responsible for deleterious
effects of cigarette smoke on CFTR expression [48]. Guimbellot et
al. showed that hypoxia in the airways led to reduced CFTR
mRNA expression and activity in vitro, and reduced CFTR mRNA
expression was also detected in mice exposed to hypoxic
conditions [49]. Rab et al. demonstrated that pro-inflammatory
environments, such as those expected in the COPD lung, induce
the unfolded protein response, and thus reduce CFTR function
[50]. Accumulation of ceramide due to the UPR was also observed
in the lungs of COPD patients and was correlated with reduced
CFTR expression in those tissues [51,52]. Further studies are
needed to establish the relative contribution of these molecular
mechanisms to acquired CFTR dysfunction in the COPD lung
and to determine if they might contribute to persistent decrements
in CFTR activity following smoking cessation.
Though these findings point to a novel therapeutic strategy for
COPD, additional investigations are needed prior to implement-
ing such a treatment paradigm. While our studies convincingly
demonstrate that a CFTR decrement is present in the upper
airway of smokers with COPD, CFTR function has not yet been
measured in the lower airway of these patients. In addition, the
relationship between lower airway CFTR activity and small
airway mucus clearance is unknown as is the effect of CFTR
dysfunction on clinical phenotype (e.g. exacerbation frequency,
lung function, and symptoms of bronchitis and dyspnea).
Establishing the phenotypic groups in which CFTR dysfunction
leads to COPD manifestations is critical, since application of
Figure 6. Schematic demonstrating the role of cigarette smoke and CFTR potentiator therapy in chronic bronchitis.
doi:10.1371/journal.pone.0039809.g006
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broad non-targeted use.
CFTR potentiators such as ivacaftor represent an attractive
therapeutic approach for individuals with smoking related lung
disease and may be particularly well suited to individuals with
chronic mucus hypersecretion. As opposed to currently available
mucolytic agents that have failed to demonstrate convincing
evidence of clinical benefit [53,54], CFTR potentiators may
overcome the limitations posed by the poor bioavailability of
pharmaceuticals administered by inhalation and the limited
activity of oral agents none of which directly augment MCC.
Because mucus stasis has been associated with excess mortality and
a more rapid decline in pulmonary function [10], this remains an
area of high therapeutic priority in COPD [55]. Further studies to
establish the phenotype associated with CFTR dysfunction among
individuals with COPD are indicated, and together with the
present findings, could form the basis for clinical intervention
using CFTR potentiators in COPD.
Supporting Information
Figure S1 (A) Representative Ussing chamber tracings from
Calu-3 cells grown at air-liquid interface, then exposed to CSE
(2%) for 24 h and studied under voltage clamp conditions as
shown in Fig. 1A. (B) Summary data of experiments shown in (A).
DIsc is shown following stimulation with forskolin (20 mM)
*P,0.05, n=8 **P,0.01, n=8.
(TIFF)
Figure S2 Cellular cAMP levels determined by colorimetric
assay in non-CF HBE monolayers stimulated with forskolin (0,
100, 300 and 1000 nM) for 10 min prior to lysis, n=3/condition.
(TIFF)
Figure S3 MUC5ac expression is altered by CSE
exposure. MUC5ac staining is shown from representative
sections of HBE cells exposed to CSE (2%) or vehicle control for
24 h. Control slides were stained in the absence of primary anti-
MUC5ac antibody.
(TIFF)
Figure S4 Effect of ivacaftor on open channel probabil-
ity. Inside-out membrane patches were obtained from NIH3T3
cells transduced with WT CFTR and single channel conductance
tracings recorded with control (i,P o=0.460.04); 0.3 mM ivacaftor
(ivacaftor; ii,P o=0.860.04); and 0.3 mM ivacaftor +20 mM
CFTRInh-172 (iii). All recordings performed in the presence of
75 nM PKA +1 mM ATP. Dotted line represents closed channel
configuration. Summary data of these experiments was shown
previously by Van Goor et al. [17].
(TIFF)
Figure S5 Effect of forskolin prestimulation on ivacaf-
tor induced Isc. Prior to ivacaftor addition, varying concentra-
tions of forskolin were administered as shown to non-CF HBE
cells, then Isc plotted following sequential addition of increasing
concentrations of ivacaftor (ivacaftor), n=3/condition.
(TIFF)
Figure S6 Effect of CSE exposure on ciliary beating. CSE
(2%, apical), ivacaftor (ivacaftor; 10 mM, basolateral), both agents,
or vehicle control was applied to primary human bronchial
epithelial monolayers for 24 hrs, and then the change in ciliary
beat frequency (CBF) from pretreatment baseline was assessed by
Hoffman contrast microscopy at 4–5 ROI for each well. N=3/
condition.
(TIFF)
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